The price increase of Chinese herbal medicines has entered the fourth round. If there is no further control, the development of the industry will be placed in a severe situation.
This is not alarmist. Jia Haibin, deputy director of the Chinese Medicine Association Information Center of the Chinese Medicine Association and deputy general manager of the Chinese herbal medicine company, admitted to the Shanghai Securities News that since 2009, Chinese herbal medicines have been continuously rising. Since March 2011, Chinese herbal medicine prices have entered the fourth round of peaks. The situation is becoming less and less optimistic. If it goes up again, the sustainable development of the Chinese medicine industry will face severe challenges.
According to the World Index Composite Index 200 index released yesterday by World Wide Web, the index rose slightly to 2833.32 points this week, up 0.19% on a week-to-week basis. However, it is worth noting that in March this year, the index was 2488 points, a short period of 2 months, soaring more than 10%.
Although the price of Chinese herbal medicines continues to rise due to the production cycle, the growth cycle of many varieties of Chinese herbal medicines exceeds 2 years or even longer. The reaction of the production end to market conditions has not been reflected in the output. For example, ginseng, even if it is planted this year, the production recovery will take 4-6 years. However, the shortage of rural labor force and rising production costs have made it difficult for the basic production of Chinese medicinal materials to recover in the short term. Therefore, the weak foundation of production is still the root cause of the continuous rise in drug prices.
Taking the first quarter of this year as an example, the prices of Chinese herbal medicines have risen significantly. Among them, the more prominent codonopsis rose from 28 yuan to 62 yuan per kilogram, Ophiopogon rose from 80 yuan to 160 yuan per kilogram, Taizi ginseng rose from 220 yuan to 325 yuan now. Yuan, Huang Jing, pine nut and other varieties rose more than 30% in the past two months. The high level of drug market does not fall and the risk of accumulation is increasing.
Drought boosting According to reports, the current drug market continues to maintain its upward trend and drought conditions are not unrelated. There was no effective rainfall for four consecutive months in Gansu, Henan, Shandong, and Anhui provinces, which drove a significant rise in the prices of real estate medicinal herbs in the drought-producing areas: Gansu real estate herbal medicine prices remained high; Henan Xiaqiu, Hawthorn, Shandong, and Henan Danshen, Quzhou daylight and wind protection are also hot trading.
As an important indicator reflecting the prices of Chinese herbal medicines and the industry's economic climate, the price index of Chinese herbal medicines launched by Cniti.com has been certified by the national science and technology sector and is the nation's first Chinese herbal medicine price index. Based on this, it generates monthly monitoring and early warning reports. From the monitoring and early warning report data, it is shown that the wild resources in Chinese herbal medicines are the most depleted signs.
For example, Jia Haibin said that 40% of China's wild Chinese herbal medicine resources are in danger of depletion in the next 5-10 years. For example, Chinese herbal medicines are "heavy buildings," and it is increasingly difficult to find them in domestic production areas. This medicinal material could only be imported from Yunnan Ruili and other ports five years ago to meet the needs of the domestic market. According to monitoring at the Ruili Port, the port's imports dropped to below 60 tons in 2010, and it has now been imported from Nepal, India and other regions.
According to the survey, the heavy building is one of the important raw materials for Yunnan Baiyao and Livzon Group. If the medicinal material is depleted, it will have an adverse effect on the normal production and operation of the company.
In addition to wild resources, homegrown varieties of Chinese herbal medicines are also in danger.
Taking Ophiopogon japonicus as an example, the yield per mu can reach 400 kilograms according to 100 yuan/kg, so that the output value per mu is expected to reach 40,000 yuan! Therefore, peasant friends have joined the large army of Ophiopogon. The peasant brothers planted in large areas will further break the balance between supply and demand. When the Ophiopogon harvested in large areas next year, the market price of Ophiopogon may have already come down, which makes it difficult for farmers to ship, reproducing a similar picture of the price of vegetables this year.
The enterprises are smashing goods, and hot money speculating on high-value Chinese herbal medicines does indeed put TCM production companies under great operating pressure.
In the opinion of Tong Zetang, the secretary of Tong Ren Tang, the price of Chinese herbal medicines is still rising in absolute terms. But the magnitude of this wave is much smaller than the crazy growth of last year. From a long-term point of view, the price of Chinese herbal medicines is still expected to return.
It is reported that in the process of increasing the price of Chinese herbal medicines, some companies have also participated in the sale of goods. A head of the purchasing department of a listed company told reporters that the price of Chinese herbal medicines had skyrocketed last year, and companies could only repress production and control demand. Originally they thought prices would fall this year, but they did not expect that not only did they not fall, but also Rising. Under the pressure of rising costs and declining profits, companies have to participate only in the sales of goods. Relevant sources disclosed to reporters, "In fact, like ginseng, Panax notoginseng and other valuable Chinese herbal medicines, some companies began to carry out stockpiling three years ago, until now. There are still large companies involved in the accumulation of Chuanxiong, heterophylla and other varieties."
It is understood that the relevant authorities of the State keep close attention to the inflated prices of Chinese herbal medicines. In the future, relevant policies will be issued to regulate the normal operation of the industry. Industry insiders believe that in the just-released “12th Five-year Plan for Pharmaceutical Circulationâ€, it is clearly stated that the company supports and establishes tracking and early warning systems for the tracking of production and sales of all varieties of medicines and key Chinese herbal medicines, and establishes a platform for the supply and supply of Chinese herbal medicines. Basic production. In time, the return of Chinese herbal medicine prices to rationality is not far away.
This is not alarmist. Jia Haibin, deputy director of the Chinese Medicine Association Information Center of the Chinese Medicine Association and deputy general manager of the Chinese herbal medicine company, admitted to the Shanghai Securities News that since 2009, Chinese herbal medicines have been continuously rising. Since March 2011, Chinese herbal medicine prices have entered the fourth round of peaks. The situation is becoming less and less optimistic. If it goes up again, the sustainable development of the Chinese medicine industry will face severe challenges.
According to the World Index Composite Index 200 index released yesterday by World Wide Web, the index rose slightly to 2833.32 points this week, up 0.19% on a week-to-week basis. However, it is worth noting that in March this year, the index was 2488 points, a short period of 2 months, soaring more than 10%.
Although the price of Chinese herbal medicines continues to rise due to the production cycle, the growth cycle of many varieties of Chinese herbal medicines exceeds 2 years or even longer. The reaction of the production end to market conditions has not been reflected in the output. For example, ginseng, even if it is planted this year, the production recovery will take 4-6 years. However, the shortage of rural labor force and rising production costs have made it difficult for the basic production of Chinese medicinal materials to recover in the short term. Therefore, the weak foundation of production is still the root cause of the continuous rise in drug prices.
Taking the first quarter of this year as an example, the prices of Chinese herbal medicines have risen significantly. Among them, the more prominent codonopsis rose from 28 yuan to 62 yuan per kilogram, Ophiopogon rose from 80 yuan to 160 yuan per kilogram, Taizi ginseng rose from 220 yuan to 325 yuan now. Yuan, Huang Jing, pine nut and other varieties rose more than 30% in the past two months. The high level of drug market does not fall and the risk of accumulation is increasing.
Drought boosting According to reports, the current drug market continues to maintain its upward trend and drought conditions are not unrelated. There was no effective rainfall for four consecutive months in Gansu, Henan, Shandong, and Anhui provinces, which drove a significant rise in the prices of real estate medicinal herbs in the drought-producing areas: Gansu real estate herbal medicine prices remained high; Henan Xiaqiu, Hawthorn, Shandong, and Henan Danshen, Quzhou daylight and wind protection are also hot trading.
As an important indicator reflecting the prices of Chinese herbal medicines and the industry's economic climate, the price index of Chinese herbal medicines launched by Cniti.com has been certified by the national science and technology sector and is the nation's first Chinese herbal medicine price index. Based on this, it generates monthly monitoring and early warning reports. From the monitoring and early warning report data, it is shown that the wild resources in Chinese herbal medicines are the most depleted signs.
For example, Jia Haibin said that 40% of China's wild Chinese herbal medicine resources are in danger of depletion in the next 5-10 years. For example, Chinese herbal medicines are "heavy buildings," and it is increasingly difficult to find them in domestic production areas. This medicinal material could only be imported from Yunnan Ruili and other ports five years ago to meet the needs of the domestic market. According to monitoring at the Ruili Port, the port's imports dropped to below 60 tons in 2010, and it has now been imported from Nepal, India and other regions.
According to the survey, the heavy building is one of the important raw materials for Yunnan Baiyao and Livzon Group. If the medicinal material is depleted, it will have an adverse effect on the normal production and operation of the company.
In addition to wild resources, homegrown varieties of Chinese herbal medicines are also in danger.
Taking Ophiopogon japonicus as an example, the yield per mu can reach 400 kilograms according to 100 yuan/kg, so that the output value per mu is expected to reach 40,000 yuan! Therefore, peasant friends have joined the large army of Ophiopogon. The peasant brothers planted in large areas will further break the balance between supply and demand. When the Ophiopogon harvested in large areas next year, the market price of Ophiopogon may have already come down, which makes it difficult for farmers to ship, reproducing a similar picture of the price of vegetables this year.
The enterprises are smashing goods, and hot money speculating on high-value Chinese herbal medicines does indeed put TCM production companies under great operating pressure.
In the opinion of Tong Zetang, the secretary of Tong Ren Tang, the price of Chinese herbal medicines is still rising in absolute terms. But the magnitude of this wave is much smaller than the crazy growth of last year. From a long-term point of view, the price of Chinese herbal medicines is still expected to return.
It is reported that in the process of increasing the price of Chinese herbal medicines, some companies have also participated in the sale of goods. A head of the purchasing department of a listed company told reporters that the price of Chinese herbal medicines had skyrocketed last year, and companies could only repress production and control demand. Originally they thought prices would fall this year, but they did not expect that not only did they not fall, but also Rising. Under the pressure of rising costs and declining profits, companies have to participate only in the sales of goods. Relevant sources disclosed to reporters, "In fact, like ginseng, Panax notoginseng and other valuable Chinese herbal medicines, some companies began to carry out stockpiling three years ago, until now. There are still large companies involved in the accumulation of Chuanxiong, heterophylla and other varieties."
It is understood that the relevant authorities of the State keep close attention to the inflated prices of Chinese herbal medicines. In the future, relevant policies will be issued to regulate the normal operation of the industry. Industry insiders believe that in the just-released “12th Five-year Plan for Pharmaceutical Circulationâ€, it is clearly stated that the company supports and establishes tracking and early warning systems for the tracking of production and sales of all varieties of medicines and key Chinese herbal medicines, and establishes a platform for the supply and supply of Chinese herbal medicines. Basic production. In time, the return of Chinese herbal medicine prices to rationality is not far away.
2L-size Carrot,2L-size Fresh Carrot,Fresh Carrot Size 2L,2L-size Red Color Carrot
Yirun Agricultural Cooperative , https://www.yiruncn.com